ALLO

Allogene is a clinical-stage allogeneic CAR-T company that has effectively zero commercial revenue (FY2025 revenue: $0, down from $22K in FY2024 and $114M in FY2021 when collaboration income still flowed). The FY2025 P&L is purely a burn-rate story: -$191M net loss, -$209M operating loss, -$149M operating cash flow, and R&D still running at $150M. Against that, the balance sheet is alarmingly thin — only $51.7M in cash and equivalents at year-end, against $293M of stockholders' equity that has been eroded -30.7% YoY by a -$2.01B accumulated deficit. Even assuming the broader $258M of current assets includes marketable securities, current cash covers roughly four months of operating burn at the FY2025 pace, which all but guarantees dilution above the already +12.2% YoY share-count creep. ROE of -65.3% is not a meaningful 'return' metric here — it is a measure of how fast equity is being incinerated.

The MD&A makes clear the entire equity value hinges on three clinical programs (ALPHA3, RESOLUTION, TRAVERSE), with ALPHA3 — the Phase 2 pivotal of cema-cel as 1L LBCL consolidation — being the load-bearing asset. The filing explicitly flags the next binary catalyst: a futility analysis comparing MRD clearance rates is expected in April 2026. That is the stock. Compounding the risk, management disclosed a Grade 5 (fatal) adverse event in the FCA arm tied to ALLO-647, forcing closure of that arm ahead of the scheduled futility analysis. While management argues the event was 'unrelated to cema-cel' and that no FC-only patients have had adenoviral hepatic failure, the company has been forced to redesign the trial mid-stream from three arms to two (~220 patients), drop ALLO-647 from the entire pipeline, and pivot future programs to the unproven 'Dagger Platform.' That is not a sign of a clean development program.